Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer

Rossi, Sabrina; Marinello, Arianna; Pagliaro, Arianna; Franceschini, Davide; Navarria, Pierina; Finocchiaro, Giovanna; Toschi, Luca; Scorsetti, Marta; Santoro, Armando

doi:10.1080/14737140.2023.2162044

Cited by 1 publication

(1 citation statement)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, ALK alterations, including fusion, rearrangement, and missense mutations, have been associated with the occurrence, rapid progression, and metastasis of carcinomas, including neuroblastoma, rhabdomyosarcoma, and non-small-cell lung cancer (NSCLC) ( van Gaal et al, 2012 ; Bresler et al, 2014 ; Schneider et al, 2023 ). Approximately 3%–8% of patients with NSCLC harbor ALK rearrangement mutations, which are conventionally considered the main driver mutations among ALK alterations ( Kapoor et al, 2023 ; Rossi et al, 2023 ). Accordingly, several ALK tyrosine kinase inhibitors (TKIs), including crizotinib, ceritinib, alectinib, lorlatinib, brigatinib, and ensartinib, have been approved for the treatment of NSCLC patients with ALK fusion mutations because of their promising efficacy in well-designed trials ( Fukui et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors

Chen

Wang

2023

Front. Pharmacol.

View full text Add to dashboard Cite

ALK gene missense mutations are conventionally considered non-driver mutations without pathological significance, and therefore, there is a lack of effective target drugs against them. The standard treatment option for patients with ALK missense mutations is chemotherapy with or without antiangiogenic agents, which usually results in unsatisfactory outcomes. Herein, we present the case of a patient with metastatic lung adenocarcinoma harboring the only missense mutation in ALK D1225N responding to two ALK-tyrosine kinase inhibitors (TKIs), namely, crizotinib and ensartinib. Our case highlights that non-small cell lung cancer (NSCLC) patients harboring the D1225N mutation may benefit from ALK-TKIs, and therefore, ALK-TKIs should be considered candidates for further line treatment.

show abstract